A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hematologic Malignancies
Sponsor: Kumquat Biosciences Inc.
A PHASE1 clinical study on Adult and Hematologic Malignancies, this trial is actively recruiting participants. The trial is conducted by Kumquat Biosciences Inc. and has accumulated 7 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Jan 2025 — May 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kumquat Biosciences Inc.
For direct contact, visit the study record on ClinicalTrials.gov .